Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 13 Triple Negative Breast Neoplasms 7 Prostatic Neoplasms 7 Neoplasms 6 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Endometrial Neoplasms 2 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostatic Diseases 1 Prostate Cancer Metastatic 1 Premenopausal HR+/HER2- Metastatic Breast Cancer 1 Pheochromocytoma 1 Pathologic Complete Response 1 Paraganglioma 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Mesothelioma, Malignant 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Hemangiosarcoma 1 Glioma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Extensive Stage Lung Small Cell Carcinoma 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 31 Gemcitabine 26 Nivolumab 20 atezolizumab 16 Cisplatin 15 avelumab 14 Carboplatin 12 Docetaxel 10 enfortumab vedotin 8 Magnetic Resonance Spectroscopy 8 durvalumab 7 Specimen Handling 7 Paclitaxel 7 Ipilimumab 6 toripalimab 5 pemigatinib 5 cabozantinib 5 vinflunine 4 sacituzumab govitecan 4 Taxes 4 Pemetrexed 4 tislelizumab 3 cabazitaxel 3 Standard of Care 3 Mitomycin 3 Injections 3 Everolimus 3 Albumin-Bound Paclitaxel 3 sapanisertib 2 olaparib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Transitional Cell × talazoparib × Clear all

NCT04678362 2025-09-22

TALASUR

Centre Francois Baclesse

Phase 2 Recruiting

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡